Jump To
Healthcare Industry Trends
Key takeaways
Our Healthcare Investments & Exits Mid-Year Report for 2024 examines the impact of fundraising, investment and exit trends on the VC-backed healthcare ecosystem.
55
Biopharma companies have landed deals of $100M and above so far this year.
2024 is on track to set the record for deals of this size within the sector.
89%
of US VC funds with a healthcare focus have hit fundraising targets in the first half of 2024.
This level of success outstrips all prior years except 2022.
More than 1 in 4
US healthcare companies that closed a venture capital deal of at least $15M reported a flat or down round in 2024.
This marks the highest proportion of down rounds in recent history.
The data
For nearly 20 years, First Citizens Innovation Banking has tracked trends in healthcare venture funding. In our latest edition of the Healthcare Investments & Exits report, we leverage our proprietary data to explore trends and offer expert commentary around fundraising, investment, M&As and IPOs in the healthcare market, as well as sector analysis for healthtech, biopharma, medical devices and diagnostics. We find that, despite strong headwinds, fundraising has remained strong so far this year, with a focus on quality over quantity.
Valuations are under the microscope
The exuberance of 2021 has given way to an era of unprecedented scrutiny for valuations, with at least 28% of deals in the US reporting down or flat rounds — the highest level seen in recent history.
With many of the unicorns formed in 2020 and 2021 yet to come back to market to raise another round, we expect to see more valuation resets ahead.
Investors prioritize quality over quantity
Extended diligence timelines and more conservative deals are making investors more confident. That confidence is translating into continued steady investment growth in 2024.
This investment activity marks the strongest start to a year outside of the pandemic investment boom of 2021 and 2022, laying the foundation for a healthy private market.
Mega deals dominate in biopharma
With 55 deals $100M and above in the first half of 2024, biopharma is on track for a record year.
The other healthcare subsectors appear to have settled into a new normal for large dealmaking after sustaining major drops from their 2021 peaks.
Explore other First Citizens Innovation Banking Reports
Reports
The Future of Healthtech 2026
Nov 09, 2026
Megan Scheffel, Adam Tweedy, Dennis He, Matt Donne, Alex Lennox-Miller, Urbashee Paul, Josh Pherigo
Reports
The Future of Fintech 2026
Oct 13, 2026
Nick Christian, Brian Foley, Julie Wagne, Sophie McNaught, Josh Pherigo, Eli Oftedal, Andrew Pardo
Reports
The Future of Climate Tech
Apr 15, 2026
Jordan Kanis, Eli Oftedal, Josh Pherigo, Andrew Pardo